Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis

site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
vertical-expand : a:0:{}
caf_enhance : 0
Drug Category : Array
Conference Category : Array
Lead Author : Alvarez ER. et al.
Published Date : 23/10/2024
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2024/10/NEDA-ULTIMATE-I-and-II-Oct-2024.pdf
Download Text :
Popup Confirmation? :
astra-migrate-meta-layouts : set
Scroll to Top